Drug intelligence / Profile preview

HLD100-B

Development stage: Unknown
Lead developer: Ironshore
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
Administration: Oral

Overview

HLD100-B is a code name for a specific formulation of dextroamphetamine, developed as a modified-release (delayed and extended release) oral medication. It is designed to provide both delayed onset and extended duration of action compared to immediate-release formulations. The primary indication for HLD100 (and its variants such as HLD100-B) is the treatment of Attention Deficit Hyperactivity Disorder (ADHD), particularly in pediatric populations. The drug aims to improve symptom control throughout the day with once-daily dosing, potentially reducing side effects associated with peak plasma concentrations seen in traditional stimulants. Clinical trials have evaluated its safety, tolerability, and efficacy in children with ADHD[5]. Developed by Ironshore Pharmaceuticals (a subsidiary or affiliate of Highland Therapeutics), this formulation represents an advancement over standard dextroamphetamine products by modifying the pharmacokinetic profile.

Other names: delayed-release and extended-release dextroamphetamine sulfate

Targets

TAAR1 (Trace amine-associated receptor 1)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on HLD100-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLD100-B.

Explore the full profile